ABSTRACT The unc-17 gene encodes the vesicular acetylcholine transporter (VAChT) in Caenorhabditis elegans. unc-17 reduction-offunction mutants are small, slow growing, and uncoordinated. Several independent unc-17 alleles are associated with a glycine-toarginine substitution (G347R), which introduces a positive charge in the ninth transmembrane domain (TMD) of UNC-17. To identify proteins that interact with UNC-17/VAChT, we screened for mutations that suppress the uncoordinated phenotype of UNC-17(G347R) mutants. We identified several dominant allele-specific suppressors, including mutations in the sup-1 locus. The sup-1 gene encodes a single-pass transmembrane protein that is expressed in a subset of neurons and in body muscles. Two independent suppressor alleles of sup-1 are associated with a glycine-to-glutamic acid substitution (G84E), resulting in a negative charge in the SUP-1 TMD. A sup-1 null mutant has no obvious deficits in cholinergic neurotransmission and does not suppress unc-17 mutant phenotypes. Bimolecular fluorescence complementation (BiFC) analysis demonstrated close association of SUP-1 and UNC-17 in synapse-rich regions of the cholinergic nervous system, including the nerve ring and dorsal nerve cords. These observations suggest that UNC-17 and SUP-1 are in close proximity at synapses. We propose that electrostatic interactions between the UNC-17(G347R) and SUP-1(G84E) TMDs alter the conformation of the mutant UNC-17 protein, thereby restoring UNC-17 function; this is similar to the interaction between UNC-17/ VAChT and synaptobrevin. C OORDINATED muscle contraction in both vertebrates and nematodes requires release of the neurotransmitter acetylcholine (ACh) from motor neurons. ACh is synthesized in motor neurons by the enzyme choline acetyltransferase (ChAT) and transported into synaptic vesicles by the vesicular ACh transporter (VAChT). Following transmitter release, cholinergic signaling is terminated primarily through the action of acetylcholinesterase (AChE), which hydrolyses the released ACh into choline and acetyl-CoA. In the nematode Caenorhabditis elegans, the ChAT and VAChT proteins are encoded by the cha-1 and unc-17 genes, respectively (Alfonso et al. , 1994b . Mutations that functionally eliminate either protein are lethal , while reduction-of-function mutations result in animals that are small, slow growing, uncoordinated, and resistant to AChE inhibitors such as aldicarb .
C
OORDINATED muscle contraction in both vertebrates and nematodes requires release of the neurotransmitter acetylcholine (ACh) from motor neurons. ACh is synthesized in motor neurons by the enzyme choline acetyltransferase (ChAT) and transported into synaptic vesicles by the vesicular ACh transporter (VAChT). Following transmitter release, cholinergic signaling is terminated primarily through the action of acetylcholinesterase (AChE), which hydrolyses the released ACh into choline and acetyl-CoA. In the nematode Caenorhabditis elegans, the ChAT and VAChT proteins are encoded by the cha-1 and unc-17 genes, respectively (Alfonso et al. , 1994b . Mutations that functionally eliminate either protein are lethal , while reduction-of-function mutations result in animals that are small, slow growing, uncoordinated, and resistant to AChE inhibitors such as aldicarb .
The unc-17 missense mutation e245 replaces a glycine with an arginine (G347R) in the ninth transmembrane domain (TMD9) of the VAChT protein . Genetic screens designed to identify mutations that improve the locomotion of e245 homozygotes have identified several loci that suppress the deleterious effects of the VAChT G347R mutation. Sandoval et al. (2006) found that the sup-8 locus corresponds to the previously characterized snb-1 gene, which encodes the v-SNARE synaptobrevin. The single sup-8 allele is associated with a missense mutation that results in a charge alteration (I97D) in the TMD of synaptobrevin. The Sandoval study suggests that synaptobrevin physically interacts with VAChT, implying a functional relationship between the synaptic vesicle fusion machinery and vesicular transport of ACh.
In the present study, we show that the sup-1 locus encodes a single-transmembrane protein that is a member of the DUF2650 subgroup of the STMC6 protein family (Pei and Grishin 2012) . Like the sup-8 mutation, the suppressing alleles of sup-1 are associated with missense mutations that replace a neutral amino acid in the TMD with a negatively charged residue. We propose that this negative charge counterbalances the positive charge associated with the UNC-17(G347R) protein. Thus, suppression of unc-17(e245) mutants by sup-1 would be mechanistically similar to suppression by sup-8. Using bimolecular fluorescence complementation (BiFC) analysis (Hu et al. 2002) , we support this model by showing that the SUP-1 protein is closely associated with UNC-17 at cholinergic synapses.
Materials and Methods

Strains and strain maintenance
Standard laboratory methods for C. elegans were described by Brenner (1974) . The wild-type strain is Bristol N2. Additional strains are listed in Supporting Information, File S1. Worms were grown on NGM-L solid media (Sun and Lambie 1997) , modified by the addition of streptomycin and mycostatin to reduce contamination, and use of a streptomycinresistant bacterial strain OP50/1 as the food source (Johnson et al. 1988 ). The pha-1(e2123) III, dpy-18(e364) III, unc-123 (jd5) III, and unc-123(jd5jd10) III mutants were obtained from the Caenorhabditis Genetics Center (University of Minnesota, Minneapolis). The sequence of the unc-17(e245) mutation was published in . The amino acid substitutions associated with the other unc-17 alleles are from , except that the amino acid substitutions associated with e284 and e464 were listed incorrectly in figure 1A of ; the correct substitutions are e284 = R60W and e464 = E98K. Isolation of sup-1 mutants is described in File S2.
Sequencing of candidate genes and sup-1 mutants
The sup-1 gene was identified by amplification of specific genomic regions from sup-1 mutant animals (Barstead and Waterston 1989) , followed by sequencing of the purified PCR product with internal primers. All DNA sequencing was performed at the Oklahoma Medical Research Foundation DNA Sequencing Core Facility, using oligonucleotides obtained from Integrated DNA Technologies (Coralville, IA).
Protein sequence analysis
Putative signal sequences and TMDs were determined using SignalP 3.0 (Bendtsen et al. 2004) and TMHMM 2.0 (Krogh et al. 2001) , respectively. Putative palmitoylation sites were determined using CSS-Palm 2.0 (Ren et al. 2008) .
Transgene production and properties
All transgene constructs for injection were generated from amplified genomic sequences and/or plasmids using a PCR fusion method (Horton et al. 1989; Hobert 2002) .
Reporters: Coding sequences for GFP and its color variants, including NLS-CFP::LacZ, were amplified from Fire expression vectors (Miller et al. 1999) . The SUP-1::YFP fusion protein contained a 19-amino-acid linker between SUP-1 and YFP.
cDNAs: The sup-1 cDNA clone yk1353e09 was obtained from Yuji Kohara (National Institute of Genetics, Mishima, Japan); it includes a complete 22-bp SL1 trans-spliced leader sequence (Krause and Hirsh 1987; Bektesh et al. 1988) , 14 bp of 59-UTR, 309 bp of coding sequence, 321 bp of 39-UTR, and a 20-bp polyA sequence. The unc-17 cDNA RM#51p has been described previously . A cytochrome b5::YFP fusion (Rolls et al. 2002) was constructed from a DNA fragment amplified from genomic DNA corresponding to C31E19.7 (RM#962p).
BiFC constructs: The pET11a-link-NGFP and pMRBAD-link-CGFP clones were generously provided by the Regan lab (Magliery et al. 2005) . The N-terminal portion of GFP (NGFP) was amplified from pET11a-link-NGFP and cloned into the Fire expression vector pPD95.77. The unc-17 coding sequence from cDNA RM#51p was cloned downstream of the NGFP sequence to yield plasmid RM#935p. The G347R mutation was introduced into RM#935p using Stratagene's QuikChange procedure (RM#938p). The NGFP was converted to NYFP using a fragment amplified from a YFP-containing clone as the primer in a QuikChange reaction. The C-terminal portion of GFP (CGFP) was amplified from pMRBAD-link-CGFP and cloned into the Fire expression vector pPD95.77. The sup-1 coding sequence from yk1353e09 (without the termination codon) was cloned upstream of the CGFP sequence, with an 8-amino-acid linker between SUP-1 and CGFP (RM#934p). The G84E mutation was introduced into RM#934p to yield plasmid RM#939p, and the CGFP was then converted to CCFP using QuikChange.
Promoters: The sup-1 promoter (Psup-1) included 3360 bp upstream of the start codon. The unc-17 promoter (Punc-17) included 3180 bp upstream of the SL1 trans-splice site (Alfonso et al. 1994a) ; it drives expression exclusively in cholinergic neurons (Rand et al. 2000) . A derivative of this promoter, designated Punc-17b, drives expression in the AS, DA, DB, VA, and VB cholinergic motor neurons of the ventral nerve cord (Charlie et al. 2006) .
DNA injections: Transgenic nematodes were generated by microinjection of DNA (plasmids and/or PCR products), essentially as described by Mello and Fire (1995) . The final DNA concentration was adjusted to 50 ng/ml by the addition of pBluescript. For BiFC experiments, we found that the optimal concentration of DNA for fluorescence was higher than for behavioral suppression. Therefore, we used an intermediate amount of DNA to achieve a balance between BiFC fluorescence and suppression. Transformation markers included the pBX plasmid, which rescues the temperature-sensitive lethality of pha-1(e2123) mutants (Granato et al. 1994) .
Behavioral assays
All behavioral measurements were performed at 22°on NGM-L plates. Swimming rates were measured using hermaphrodites raised at 20°as described previously . Acute response to 2 mM aldicarb (2-methyl-2- [methylthio] proprionaldehyde-O-[methylcarbamoyl]oxime; Chem Service, West Chester, PA) was measured as described previously (Lackner et al. 1999; Mullen et al. 2007) . Statistical significance tests used the Student's t-test.
Immunofluorescence staining
Nematodes were stained using a modified freeze-fracture procedure as previously described (Duerr et al. 1999; Mullen et al. 2006) . Antibodies used in this study include chicken polyclonal (C96) and mouse monoclonal (mAb1403) a-UNC-17 antibodies (Duerr et al. 2008) . Secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, PA).
Microscopy and imaging
Live worms were immobilized in acrylamide with 0.05% sodium azide. Confocal images were collected on a Leica TCS NT confocal microscope. Lower-resolution images were collected with a 40· Plan Fluotar 1.0 numerical aperture (NA) oil immersion objective, at 512 · 512 or 1024 · 1024 pixels, with 0.5 micrometer Z-steps. Higher-resolution images were collected with a 63· Plan APO 1.4 NA oil immersion objective, at 512 · 512 pixels, with 4· zoom, and 0.2-mm Z-steps. Images were cropped to size, assembled, and annotated using Adobe Photoshop CS2. Digital manipulations were limited to rotating and cropping (Photoshop Bicubic) of images, as well as minor level adjustments.
Quantification of anti-UNC-17 staining was performed on confocal images of N2 and mutant worms that were grown under the same conditions, fixed and stained together, and imaged on the same day with the same imaging parameters. A maximum projection of each confocal series was used for analysis. Images were opened in Photoshop CS2 and a fixed size rectangular marquee tool was used to select the nerve ring in each image. Images were cropped with no change in resolution and saved in tif format. Cropped images were imported into ImageJ and the analyze . histogram function was used to create histograms of intensity values. The list function was then used to create lists of pixel intensities and counts; values were copied to Microsoft Excel 2010. Each intensity value was multiplied by the count (number of pixels with that intensity value) and these weighted values were summed to obtain a summation of the pixel intensity for each image. These summed values were then normalized against the appropriate wild-type (N2) values. Similar results were obtained by simply determining the mean pixel intensity of each cropped image and normalizing against the appropriate wild-type value.
Results
Allele-specific suppression of unc-17 mutations by a dominant sup-1 mutation To identify proteins that interact with UNC-17/VAChT, we performed genetic screens for mutations that suppress the growth and movement deficits of unc-17(e245) mutants (see Supporting Information, File S2 for details). e245 mutant animals grow slowly and are extremely uncoordinated; therefore, suppressed animals are readily identifiable by their larger size and improved movement. We identified several extragenic suppressors, and genetic analysis revealed that most of the suppressor mutations were dominant, unlinked to unc-17, and had no obvious phenotypes in the absence of the unc-17 mutation. A number of the suppressor mutations mapped to a region of LG III approximately three map units from dpy-18. Although the dominant suppression and lack of other phenotypes made complementation testing impractical, these mutations appeared to represent alleles of the same gene, designated sup-1.
Two of the most obvious phenotypes associated with the unc-17(e245) mutation are uncoordinated locomotion (both crawling and swimming) and resistance to AChE inhibitors (Brenner 1974) . To quantify the effects of one of the sup-1 alleles (e995) on unc-17(e245) phenotypes, we measured the swimming behavior as well as the onset of paralysis following exposure to the AChE inhibitor aldicarb. For both phenotypes, the suppressor mutation restored 70% of the wild-type function (Figure 1 ). We then characterized the allele specificity of the sup-1(e995) mutation; these results are summarized in Table 1 and details are provided in Table  S1 . We found that only e245 and other alleles conferring the same G-to-R protein sequence change (e359 and p300) were suppressed by sup-1(e995). As noted earlier, the suppression by sup-1 is dominant; sup-1/+; unc-17 animals are nearly wild type in appearance and behavior (Figure 1) .
The dominance of the sup-1 suppressor mutations suggested that they were gain-of-function mutations. To examine the possible loss-of-function phenotype for this gene, a screen for loss of the dominant e245 suppression by sup-1(e995) was performed (see File S2 for details). This screen yielded a putative second site mutation of sup-1, e2636 in cis to e995. The double mutant sup-1(e995e2636) exhibited no obvious abnormalities as a homozygote and had no suppressive effect on unc-17(e245) (Figure 1 ).
The sup-1 gene encodes a small transmembrane protein
We mapped the e995 mutation to the right arm of chromosome III (12.08 6 0.598 cM). We then used a candidate gene sequencing approach to identify sequence alterations associated with three independent sup-1 mutations (see File S2). We found that the sup-1 gene corresponds to the open reading frame Y41C4A.13; the molecular identity of the gene was confirmed by transgenic expression experiments (see below). The sup-1 gene has three exons and spans 3949 base pairs (bp) of genomic sequence ( Figure 2A) ; sup-1 transcripts are trans-spliced to the SL1 leader sequence and are 650 bp in length.
The predicted SUP-1 protein is a small type I membrane protein (103 amino acids) with a putative 16-amino-acid signal peptide, a cysteine-rich N-terminal extracellular or lumenal domain, a transmembrane segment, and a small C-terminal cytoplasmic region ( Figure 2B ). The lumenal domain contains a pattern of cysteines followed by a tryptophan and a transmembrane segment [C(X) 10 CC(X) 6 CC (X) 5 W + TM]; this corresponds to the "nematode-specific" DUF2650 protein family (DUF is a PFAM designation denoting "domain of unknown function"). In addition to the pattern of lumenal cysteines, SUP-1 has a short (7 amino acid) cytoplasmic C-terminal tail with 3 basic amino acids and three cysteines ( Figure 2B and Figure S1 ); each of these cysteines matches a consensus for palmitoylation (Ren et al. 2008) .
Several other genes in the C. elegans genome encode small DUF2650 proteins with varying degrees of similarity to SUP-1 ( Figure S2 ); some of these proteins also possess short basic C-terminal tails containing potentially palmitoylated cysteines. Genes encoding similar "SUP-1-like" proteins and DUF2650 domains are found in most or all nematode genomes (and in the planarian Schmidtea mediterranea). Although genes encoding DUF2650 protein domains have not been identified in mammalian genomes, DUF2650 proteins represent a subfamily of a large group designated STMC6 proteins, and different STMC6 subfamilies are found in most animal phyla (Pei and Grishin 2012) .
Sequence analysis of sup-1 mutations
We identified the sequence changes associated with the three sup-1 mutant alleles ( Figure 2B ). The suppressor alleles e995 and md44 are associated with identical G-to-A transitions that change a glycine residue to a glutamic acid (G84E) in the SUP-1 TMD. The putative null allele e995e2636 contains both the original G84E mutation and a second G-to-A transition that introduces a nonsense mutation in exon 2 (W58*). For convenience, we will refer to sup-1(e995e2636) as sup-1(null).
Expression and localization of the sup-1 gene product
Using a sup-1 transcriptional reporter (FRM466, Figure 2A ), we found that sup-1 is expressed in a subset of C. elegans neurons and muscles ( Figure 3 ). Most or all of the SUP-1 + neurons are cholinergic, including cholinergic motor neurons in the ventral nerve cord, as well as a subset of cholinergic head neurons ( Figure 3 ). Expression was also noted in the anterior sublateral (SAB) neurons and at least a subset of the body sublateral neurons. Nonneuronal expression of sup-1 appeared to be limited to the body wall muscles.
To examine the subcellular localization of the SUP-1 protein, we took advantage of the suppressor activity associated with the G84E mutation and generated a transgenic SUP-1 (G84E)::YFP fusion protein under the control of the sup-1 promoter. This construct (FRM260, Figure 2A ) was introduced into an unc-17(e245) mutant background. The SUP-1 (G84E)::YFP mutant fusion protein significantly suppressed the unc-17(e245) mutant phenotype (swimming rate improved from 1.5 6 1.4% of wild type to 76.9 6 7.4%; n = 20), suggesting that the fusion protein is functional. We did not observe any significant differences in distribution between the wild-type and G84E mutant SUP-1::YFP fusion proteins. Wild-type SUP-1::YFP fluorescence in cholinergic neurons and body wall muscles was first observable in embryos and persisted throughout development (Figure 4) . In cholinergic neurons, we observed enrichment of SUP-1 in synaptic regions ( Figure 4 , A and B), although fluorescence was also observed in processes and cell bodies.
The presence of SUP-1::YFP in both neurons and muscles made it difficult to determine the precise subcellular localization of the protein. Therefore, we expressed SUP-1:: YFP specifically in the cholinergic motor neurons of the ventral nerve cord, and we determined that the distribution of the SUP-1 fusion protein in cell bodies did not have any significant overlap with cytochrome b5, a marker for the 
The amino acid substitutions associated with the unc-17 alleles are from and , except as noted in Materials and Methods. See Table S1 for details. Suppression specificity experiments were performed before the sequence alterations associated with the mutations had been determined.
endoplasmic reticulum (Rolls et al. 2002) . Rather, the SUP-1 fusion protein in cell bodies appeared to be restricted to the plasma membrane (Figure 4 , D-F). In the body wall muscles, SUP-1::YFP also appeared to be localized to the plasma membrane ( Figure 4A ).
sup-1 loss-of-function mutants sup-1(null) mutants are viable and superficially wild type in appearance, development, and behavior. We found that sup-1 null mutants have only a modest (23%) deficit in swimming behavior ( Figure 1A ) and they do not differ appreciably from wild-type animals in their response to aldicarb ( Figure  1B ). Therefore, although sup-1 is expressed in many cholinergic neurons, sup-1(null) mutants have at most a minor deficit in cholinergic neurotransmission. We considered the possibility that the mild phenotype of sup-1 null mutants might reflect some level of overlapping function between SUP-1 and similar "SUP-1-like" proteins ( Figure S2 ). However, although some of these proteins are expressed in restricted subsets of neurons, none of the SUP-1-like proteins has an expression pattern consistent with acting redundantly with SUP-1 (details in File S2).
Effects of sup-1 mutations on UNC-17 abundance and trafficking
We previously demonstrated by immunostaining that UNC-17 protein is less abundant in e245 mutants (Sandoval et al. 2006) . Additional experiments demonstrated that in unc-17 (e245); sup-1(e995) double mutants, both the levels and localization of UNC-17 protein appeared normal ( Figure  5 ). The restoration of UNC-17 levels in unc-17(e245); sup-1(e995) double mutants raised the possibility that sup-1 might suppress the unc-17 mutant phenotype simply by increasing the abundance of the G347R mutant protein. We tested this hypothesis in two ways. First, we overexpressed the G347R protein, with or without an N-terminal YFP tag, in an unc-17(e245) mutant background. We found that overexpression of the G347R protein increased the amount of UNC-17 immunoreactivity, but did not improve the behavioral deficits of the unc-17(e245) animals ( Figure 6 ). Next, we examined the behavior of unc-17(md1447) mutants; the md1447 mutation is a deletion in the 39-UTR of the unc-17 gene that results in a severe reduction in UNC-17 immunostaining (Alfonso et al. 1994a) . Although the decrease in UNC-17 immunoreactivity in this mutant is more profound than in unc-17(e245) (Figure S3 ), we found that the behavioral defects are considerably less severe ( Figure  6C ). Based on these results, it is unlikely that increasing the abundance of the mutant UNC-17 is responsible for the suppression of the e245 behavioral phenotype. We also determined that sup-1(null) mutants have approximately wild-type levels and localization of UNC-17 by immunostaining (data not shown). We conclude that SUP-1 is not required to maintain UNC-17 levels or localization in a wild-type genetic background.
The SUP-1 and UNC-17 proteins are closely associated in synaptic vesicles
The genetic interactions between sup-1 and unc-17 are very similar to the interactions between snb-1 and unc-17 reported by Sandoval et al. (2006) , and we therefore speculated that the UNC-17 and SUP-1 proteins might also be in close physical proximity, or perhaps interact, in synaptic vesicles. To test this hypothesis, we used BiFC analysis to look at association between SUP-1 and UNC-17 in the C. elegans cholinergic nervous system. This approach has been used in a number of organisms, including C. elegans, to visualize protein-protein interactions (Hu et al. 2002; Shyu et al. 2008) . For these experiments, an N-terminal partial peptide from YFP (NYFP) was fused to the N terminus of UNC-17, and a C-terminal partial peptide from CFP (CCFP) was fused to the C terminus of SUP-1. We expressed the NYFP::UNC-17 fusion protein under the control of the unc-17 promoter and the SUP-1::CCFP under the control of the sup-1 promoter. Neither fusion protein by itself gave rise to detectable fluorescence, but when the two wild-type fusion proteins were coexpressed, fluorescence was observed in synapse-rich regions of the cholinergic nervous system, including the nerve ring and dorsal and ventral nerve cords ( Figure 7A) . Coexpression of the SUP-1(G84E)::CCFP and NYFP::UNC-17(G347R) fusion proteins gave similar results ( Figure 7B ), although more fluorescence was observed in cell bodies than was observed with the wild-type combination.
These results, together with the genetic data, suggest that UNC-17 and SUP-1 are close together at the synapse and may physically interact. Potentially, the G347R mutation may disrupt physical interactions between UNC-17 and SUP-1, and the compensatory SUP-1(G84E) mutation may then restore these interactions. We tested this hypothesis by coexpressing NYFP::UNC-17(G347R) and SUP-1(WT):: CCFP. We note that Morell et al. (2008) have shown that inhibiting protein-protein interactions between BiFC partners results in a significant reduction in fluorescence. However, we observed strong BiFC fluorescence ( Figure 7C) , which was qualitatively similar to that observed when the two mutant proteins were coexpressed ( Figure 7B ). We conclude that the G347R mutation does not significantly disrupt the ability of UNC-17 and SUP-1 fusion proteins to produce BiFC fluorescence.
The transmembrane domain of SUP-1 mediates interaction with UNC-17/VAChT
To identify the specific regions of the SUP-1 protein that facilitate interaction with UNC-17, we generated deletion derivatives of the SUP-1(G84E)::CCFP construct. These were co-injected with the NYFP::UNC-17(G347R) construct and crossed into an unc-17(e245) mutant background. The resultant strains were assayed for suppression of the unc-17 mutant swimming phenotype and for BiFC; these results are summarized in Figure 8 . We found that deletion of the C-terminal (cytoplasmic) domain had little effect on suppression or BiFC fluorescence. In contrast, deletion of the lumenal region between the signal sequence and the TMD eliminated suppression and most of the BiFC fluorescence. The little remaining fluorescence was restricted to the cell bodies, presumably due to improper trafficking of the SUP-1 protein.
To test this hypothesis, we replaced the signal peptide and N-terminal domain of SUP-1 with the analogous region from SNT-1/synaptotagmin (Nonet et al. 1993; Mathews et al. 2007) , an unrelated synaptic vesicle protein with the same (type I) membrane topology. We found that this chimeric protein suppressed the unc-17(e245) mutant phenotype and restored BiFC fluorescence (Figure 8 ). Although the lumenal domain of SUP-1 appears to be required for proper trafficking to synaptic vesicles, neither the lumenal nor the cytoplasmic domains are required for interaction with UNC-17. It therefore appears that the interaction with UNC-17 is mediated entirely through the SUP-1 TMD, and simply trafficking the TMD to synaptic vesicles permits the SUP-1-UNC-17 suppressive interaction.
Discussion
sup-1 mutants
We show here that alleles of the sup-1 gene strongly suppress specific unc-17 mutations (Figure 1 ). The suppressor alleles are associated with a G-to-E substitution (G84E) in the SUP-1 TMD and suppress mutations associated with a Gto-R substitution (G347R) in the ninth TMD of UNC-17/ VAChT ( Figure S4 ). Other unc-17 alleles, including a G-to-R substitution elsewhere in the protein, are not suppressed (Table 1 ). The suppression is dominant ( Figure 1A) , and transgenic expression of SUP-1(G84E) restores locomotion and swimming behavior in unc-17(e245) mutant animals.
We note that additional unc-17 mutant phenotypes have been reported, including reduced growth rate, small adult size, decreased pharyngeal pumping, reduced defecation rate, and constitutive egg laying Avery 1993; Nguyen et al. 1995; Bany et al. 2003) , and these phenotypes are also suppressed by sup-1 mutations (not shown).
The SUP-1 protein SUP-1 is a member of the DUF2650 subfamily of STMC6 (single-transmembrane proteins with conserved 6 cysteines) family of proteins; STMC6 proteins are single-transmembrane proteins that have a conserved pattern of cysteines in their N-terminal domains (Pei and Grishin 2012) . In addition, many members of the family have cysteine residues predicted to be palmitoylated near the cytoplasmic face of the transmembrane segment. Like other members of the STMC6 family, SUP-1 is predicted to be a type I transmembrane protein (extracellular or lumenal N terminus, and cytoplasmic C terminus). This predicted topology is consistent with our BiFC data: we observed fluorescence with the CCFP moiety on the C terminus of SUP-1 and the NYFP moiety on the cytoplasmic N terminus of UNC-17.
As noted earlier, SUP-1 is also a member of the DUF2650 subfamily and is the first DUF2650 family member to be characterized in any detail. Although the PFAM description for this domain suggests that it is found only in nematodes, we found several apparent DUF2650 proteins in the genome of planarian S. mediterranea ( Figure S1 ).
Our reporter studies indicate that SUP-1 is expressed in a subset of neurons and in body wall muscles ( Figure 3) ; most or all of the SUP-1 + neurons are cholinergic, including the ventral nerve cord and sublateral motor neurons. In these cholinergic neurons, SUP-1 is present in processes, and based on the genetic and BiFC interactions between SUP-1 and UNC-17, at least some SUP-1 is localized to synaptic vesicles.
The UNC-17(G347R) mutant protein
We propose that the primary effect of the G347R amino acid substitution is a disruption of UNC-17 protein conformation; this could be a consequence of the increased bulk of the arginine residue and/or the presence of an additional charged amino acid in TMD9. The altered conformation leads to decreased protein stability and reduced transport of ACh; collectively, these confer the G347R mutant phenotype. The reduced loading of ACh into synaptic vesicles leads to the obvious behavioral phenotypes, including uncoordinated crawling, decreased swimming rate, and aldicarb resistance (Figure 1) .
The reduced level of UNC-17 immunostaining in unc-17 (e245) mutants ( Figure 5 ) suggests that the mutant protein is turned over faster than the wild-type protein; however, our results do not address the specific subcellular site of UNC-17 protein degradation. One possibility is that the G347R protein is correctly trafficked to synaptic vesicles, but is less stable than the wild-type protein. Another possibility is that the aberrant conformation of the mutant protein is recognized by a cellular quality control mechanism in the ER, where the G347R protein would be targeted for degradation. However, since a complete lack of synaptic UNC-17 protein is lethal , at least some of the mutant protein must be properly trafficked. We suggest that the cellular, rather than synaptic, localization of overexpressed UNC-17(G347R) protein ( Figure 6B ) is consistent with the latter model. Presumably, the aberrant conformation of the overexpressed mutant protein still targets it for degradation, but the sheer amount of mutant protein exceeds the capacity of the protein degradation pathway, and the UNC-17(G347R) protein accumulates in the ER. In contrast, when wild-type UNC-17 is overexpressed, most of the protein traffics normally to synapses and is functional, resulting in increased ACh release and hypersensitivity to aldicarb (Sandoval et al. 2006) . Although G347R mutants have reduced synaptic levels of UNC-17 protein and severely impaired behavior, and the SUP-1(G84E) protein suppresses both of these phenotypes (Figures 1 and 5) , we show that the decreased abundance of UNC-17 is not the primary cause of the behavioral phenotypes; it is therefore unlikely that the increase in protein abundance in animals expressing SUP-1(G84E) is responsible for suppression of the behavioral phenotypes.
Interaction between UNC-17 and SUP-1 proteins
According to current structural models of VAChT proteins (Vardy et al. 2004; Law et al. 2008) , TMD9 is an "external" TMD and is therefore in a position to interact with TMDs of other proteins. Our genetic data suggest that the TMD of SUP-1 can interact with TMD9 of UNC-17/VAChT. Using BiFC, we show that the wild-type UNC-17 and SUP-1 proteins are closely associated at synapses, as are the two mutant proteins (Figure 7, A and B) . We also show that the G347R mutation in TMD9 of UNC-17 does not prevent close association with the wild-type SUP-1 protein at synapses ( Figure 7C ).
BiFC data are normally interpreted as a measure of specific protein-protein interactions (Hu et al. 2002; Shyu et al. 2008) . Alternatively, the observed BiFC interactions may actually reflect protein proximity and not necessarily protein interaction (Bhat et al. 2006 ). If two proteins are able to diffuse freely, then prolonged proximity would require protein interaction; however, when both proteins are spatially constrained in the synaptic vesicle membrane (Takamori et al. 2006) , then proximity-based BiFC interactions may be passive and would not necessarily reflect functional interactions. Molecular modeling of the NYFP::UNC-17 and SUP-1::CCFP proteins suggests that fluorescence complementation could occur in synaptic vesicles without direct physical contact between the fusion partners (J. Manjarrez, personal communication). Therefore, although the BiFC data indicate that UNC-17 and SUP-1 are in close proximity in synaptic vesicle membranes, we cannot determine at this point whether there are direct protein-protein interactions between the wild-type UNC-17 and SUP-1 proteins. More generally, we suggest that even though BiFC studies with synaptic vesicle membrane proteins may not necessarily reflect functional interactions, they can nevertheless be useful for assessment of protein trafficking and colocalization.
We currently favor the model that the interaction between wild-type UNC-17 and wild-type SUP-1 is passive, and the observed BiFC reflects the physical proximity of the two proteins. The wild-type SUP-1 protein does not appear to be involved in the trafficking or localization of UNC-17 protein, because there is not a significant reduction in synaptic levels of wild-type UNC-17 in sup-1 null mutants (not shown). Similarly, since the sup-1 null mutant does not have a strong cholinergic phenotype, wild-type SUP-1 is unlikely to have a significant effect on vesicular ACh transport, although we cannot exclude the possibility that other proteins function redundantly with SUP-1.
However, in addition to this proposed passive interaction, there is the charge interaction that occurs between mutant forms of the two proteins. It is likely that the formation of the arginine-glutamic acid ion pair ( Figure S4 ) helps restore the conformation of UNC-17, either by reorienting the bulky arginine or by neutralizing the additional charge in TMD9, and this interaction offsets most of the adverse G347R-mediated effects on UNC-17 stability and ACh transport. Presumably, for the UNC-17(G347R) protein to be stabilized and to be trafficked properly, the two mutant proteins would need to "encounter" each other during an early stage of trafficking, and they would likely remain associated all the way to the synapse.
We have shown that the suppressive interaction between the mutant SUP-1 and UNC-17 proteins does not require either the SUP-1 lumenal or cytoplasmic domains and presumably requires only that the SUP-1 TMD containing the G-to-E substitution be trafficked to synaptic vesicles ( Figure  8 ). Furthermore, we note that the SNB-1(I97D) mutant protein also provides essentially complete phenotypic suppression of UNC-17(G347R) mutant phenotypes (Sandoval et al. 2006 ). Since SUP-1 is a type I transmembrane protein and SNB-1 is a type II protein, it appears that the relative orientation of the interacting transmembrane helices does not affect the effectiveness of the suppressive charge interaction. One might therefore conclude that the only requirements for extragenic suppression of the G347R mutant are: (1) a transmembrane protein correctly trafficked to synaptic vesicles in cholinergic neurons and (2) an aspartate or glutamate residue approximately in the middle of the TMD. However, transgenic expression of an engineered synaptotagmin [SNT-1(I85D)] containing an isoleucine-to-aspartate substitution in the middle of the TMD provided only a small level of suppression of UNC-17(G347R) phenotypes (Sandoval et al. 2006) . It therefore appears that there are additional requirements for the suppressing TMDs.
The function of SUP-1
Although the gain-of-function sup-1 alleles have been useful in understanding some features of a specific type of UNC-17 alteration, the sup-1 loss-of function phenotypes have not been very informative about normal SUP-1 function. In particular, we have no information about the role of SUP-1 in the body muscles: muscle structure and function appear normal in sup-1(null) mutants. In the nervous system, it is possible that SUP-1 plays a role in trafficking, sorting, or stabilization of UNC-17, but in that case, there must be other proteins whose functions overlap those of SUP-1.
The STMC6 family of proteins is large and heterogeneous, and it is difficult to infer much about SUP-1 function based on its membership in this group. The STMC6 family includes the Shisa, Shisa-like, WBP1/VOPP1, TMEM92, CYYR1, CX, and DUF2650 protein subfamilies, and family members are implicated in a variety of biological processes and pathological conditions, including embryonic development, synaptic plasticity, apoptosis, and cancer; the current mechanistic interpretation is that many STMC6 proteins are adaptors that regulate membrane proteins such as cell surface receptors (Pei and Grishin 2012) . We also note that SUP-1 also displays some intriguing structural similarities to progranulins, cysteine-rich proteins that regulate a variety of cellular processes (Bateman and Bennett 2009) .
In summary, SUP-1 is a member of the DUF2650 subfamily of STMC6 proteins, and a glycine-to-glutamic acid substitution Figure 8 Structure-function analysis of SUP-1. Deletions were generated in the SUP-1(G84E)::CCFP expression construct to identify regions of the SUP-1 protein that facilitate interaction with the UNC-17(G347R) mutant protein.
The SUP-1 signal peptide, lumenal domain, transmembrane segment (TM, with a yellow diamond indicating the location of the G84E substitution), and cytoplasmic region (Cy) are indicated. Also indicated are the vectorderived spacer segment (Sp) and the C-terminal peptide of CFP (CCFP). DN terminus, D20-71; DC terminus, D97-103. For the SNT-1::SUP-1 chimera, the N-terminal domain of SUP-1 (including signal peptide) was replaced with the analogous domain from SNT-1 (residues 1-72). Constructs were coinjected with the NYFP::UNC-17(G347R) expression construct, and the resulting extrachromosomal arrays were crossed into an unc-17(e245) mutant background. Complete genotypes are described in File S1. Constructs were assayed for suppression of the unc-17(e245) swimming deficit and for BiFC fluorescence. Suppression was defined as a .20-fold increase in swimming rate (body bends per minute) relative to the unc-17(e245) control. For BiFC assays, +, bright synaptic fluorescence; 2, faint/undetectable synaptic fluorescence.
(G84E) in the TMD of SUP-1 suppresses the behavioral and protein abundance phenotypes associated with a glycine-toarginine amino acid substitution (G347R) in the ninth TMD of UNC-17/VAChT. We propose that electrostatic interactions between the UNC-17(G347R) and SUP-1(G84E) TMDs ( Figure S4 ) restore UNC-17 stability, and function; this form of suppression is mechanistically similar to a previously characterized interaction between UNC-17/VAChT and synaptobrevin. Figure S1 Alignment of SUP-1 protein sequence with homologs from other (mostly) nematode species. Predicted signal sequences are shaded green, predicted transmembrane domains are shaded blue, the DUF2650 conserved pattern of lumenal cysteines is shaded yellow, and cytoplasmic cysteines predicted to be palmitoylated are red.
GENETICS
Figure S2
Aligned protein sequences of SUP-1 (Y41C4A.13) and C. elegans SUP-1-like proteins (labeled with their cosmid designations). As in the previous figure, predicted signal sequences are shaded green, predicted transmembrane domains are shaded blue, the DUF2650 conserved pattern of lumenal cysteines is shaded yellow, and cytoplasmic cysteines predicted to be palmitoylated are in red. The C-terminal 18 amino acids of F42C5.6 and the C-terminal 45 amino acids of R10E11.9 have been truncated for ease of presentation. 
FIGURE S4
Proposed interactions between the UNC-17 and SUP-1 proteins. UNC-17 is a twelve-pass transmembrane protein; the e245, e359, and p300 alleles are associated with identical missense mutations (G347R) that introduce a positive charge in the ninth TMD. SUP-1 is a Type I single-transmembrane protein; suppressing alleles of sup-1 are associated with identical missense mutations (G84E) that introduce a negative charge in the transmembrane segment. We propose that the TMDs of the two proteins interact (inset), and the negatively charged glutamic acid of SUP-1(G84E) neutralizes the positively charged arginine of UNC-17(G347R), facilitating proper conformation and function of the transporter. The N-and C-termini of each protein are indicated, and the predicted SUP-1 signal peptide is shown in green. The curved arrows in the inset represent the direction of translation of each protein; note that the interacting TMDs are anti-parallel.
File S1.
Strains used in these studies
The reference strain for unc-17(e245) IV (outcrossed 6x) is RM908.
The reference strain for sup-1(e995) III (outcrossed 7x) is RM3670.
The reference strain for sup-1(md44) III (outcrossed 3x) is RM3277.
The reference strain for sup-1(e995 e2636) III (outcrossed 6x) is RM3571.
The unc-17 strains used for the isolation of suppressor mutations were:
CB933: unc-17(e245) IV
PR1443: unc-17(p300) dpy-13(e184) IV
The strain used for DNA sequencing to identify the sup-1 gene was RM921: dpy-18(e364) sup-1(e995) III; 
) IV
The strains used to assess behavioral suppression and protein abundance (Figures 1 and 5) were:
N2: wild type File S2.
Supporting methods and results
Isolation of suppressors of unc-17(e245):
We performed several genetic screens for mutations that suppress the growth and movement deficits of unc-17(G347R) mutants. As described previously, the e245 and p300 alleles are associated with the same G347R sequence alteration Zhu et al. 2001). unc-17(e245) or unc-17(p300) dpy-13(e184) L4 homozygotes were mutagenized with 50 mM ethyl methanesulfonate (EMS) and plated onto 100 mm NGM plates. unc-17 mutant animals grow slowly and are highly uncoordinated; suppressed progeny were identified by their larger size and improved movement, and we identified several dominant extragenic suppressors. In particular, the e995 mutation (isolated against e245) and the md44 mutation (isolated against p300) both mapped to LGIII.
Isolation of a putative sup-1(null) mutation:
The e995e2636 allele was isolated by mutagenizing a strain with genotype sup-1(e995) ; unc-17(e245) him-8(e1489) .
Mutagenized males were then crossed with females with the genotype dpy-18(e499); unc-17(e245) fem(hc17); xol-1(y9). The only progeny of this cross are hermaphrodite cross-progeny, which are homozygous for unc-17(e245) and heterozygous for sup-1(e995). Therefore, the cross progeny are non-Unc, unless the sup-1(e995) mutation has been over-ridden, in which case the animal will be Unc. About 4000 progeny were screened for Unc progeny. Seven candidate Uncs were picked, of which six produced some wild-type self-progeny, suggesting that they were mosaic or carried a dominant Unc mutation. The seventh bred true, with a standard Unc-17 phenotype. Single Unc non-Dpy progeny were picked, of which 2/9 segregated no Dpy Uncs, and these two were therefore presumed to be homozygous with the genotype sup-1(e995e2636) ; unc-17(e245) . One of these was used to establish the strain CB5265. This strain was then outcrossed six times to remove possible background mutations; the outcrossed strain was designated RM3571.
Further experiments suggested that e2636 is indeed a sup-1 null or severe loss of function allele, rather than a revertant to the wild-type allele. An outcrossed strain CB5285 with genotype sup-1(e995e2636); unc-17(e245) was mutagenized with EMS to select for suppressors. None was found, apart from a partial same-site revertant of unc-17(e245) itself, whereas a parallel control experiment with unc-17(e245) yielded numerous suppressors (0/16 experimental versus 16/16 control 100 mm plates).
This result suggested that sup-1 locus had lost function, and therefore could no longer be mutated to create a dominant e245
suppressor. After the sup-1 locus was cloned (see below), the e2636 allele was sequenced, and was found to be associated with both the original G84E mutation and a nonsense mutation in exon 2 (W58*).
Candidate gene strategy to identify the sup-1 gene:
Mapping experiments indicated that sup-1 mapped to the right arm of chromosome III (12.09 ± 0.60 cM). This placed sup-1 (with 95% confidence) in a region between 11.49 and 12.69 cM, which corresponds to a physical distance of 149 kb and includes 24 protein-coding genes. Genes were excluded as candidates if the predicted protein did not include a transmembrane domain, if there were RNAi data suggesting that null alleles were lethal, or if there were data indicating that the protein was not expressed in the nervous system. Genomic DNA was isolated from the RM921 strain (dpy-18(e364) sup-1(e995) ; unc-17(e245) ) and used as a template for the PCR amplification of 1-2 kb regions, which were then sequenced and compared to the canonical wild-type C. elegans genome. We identified a sequence alteration associated with the e995 allele in the Y41C4.13 open reading frame. We then sequenced the md44 and e995e2636 alleles, and identified sequence alterations in the same open reading frame. The identity of the sup-1 gene was confirmed by transformation experiments: microinjection of a genomic fragment from RM921 animals containing the Y41C4.13 open reading frame with the e995 mutation suppressed the unc-17(245) phenotype.
PCR-based method for identification of point-mutants:
For outcrossing and generation of double mutants, the presence of mutant and wild-type alleles was determined in parallel reactions using a PCR-based point-mutant detection method (Qiang et al. 2002) . For each reaction, either the mutant-specific primer or the wild-type-specific primer was paired with the "common" primer as indicated. 
sup-1 is not unc-123:
A previous report (Walthall et al. 1993) suggested that the unc-123 and sup-1 loci might correspond to the same gene. We ZK353.2: The reporter had 2130 bp of upstream sequence driving expression of NLS-CFP. We observed fluorescence in the vulva and in the tail; the tail fluorescence may be the anal or intestinal muscles. In addition, we also observed fluorescence in a few cells in the head; these may be interlabial neurons, or sheath and socket cells.
K06B4.3: The reporter had 1122 bp of upstream sequence driving expression of NLS-CFP. We observed extremely faint fluorescence, including in cells around the pharynx; these may be pharyngeal cells or neurons.
